Chitosan and alginate nanoparticles as oral insulin carrier

Chitosan and alginate nanoparticles as oral insulin carrier

The possibility of administering insulin orally instead of through painful subcutaneous route has been investigated over years in the arena of diabetes medicine. Nanoparticles, microparticles, hydrogel, capsule, tablet and film patch are dosage forms designed to deliver insulin orally. They are larg...

Full description

Bibliographic Details
Published in:Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities
Main Author: Wong T.W.; Mandal U.; Shen L.-J.
Format: Book chapter
Language:English
Published: Springer-Verlag Berlin Heidelberg 2012
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901035283&doi=10.1007%2f978-3-642-29265-1_11&partnerID=40&md5=cdea40bc1d4d8b2c3f84d719798b4ef1
id 2-s2.0-84901035283
spelling 2-s2.0-84901035283
Wong T.W.; Mandal U.; Shen L.-J.
Chitosan and alginate nanoparticles as oral insulin carrier
2012
Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities
9.78364E+12

10.1007/978-3-642-29265-1_11
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901035283&doi=10.1007%2f978-3-642-29265-1_11&partnerID=40&md5=cdea40bc1d4d8b2c3f84d719798b4ef1
The possibility of administering insulin orally instead of through painful subcutaneous route has been investigated over years in the arena of diabetes medicine. Nanoparticles, microparticles, hydrogel, capsule, tablet and film patch are dosage forms designed to deliver insulin orally. They are largely formulated with polymeric adhesive, protease inhibitor, insulin aggregation inhibitor and functional excipients to induce transcellular, paracellular, Peyers patches or receptor mediated transport of insulin in gastrointestinal tract. This review probes into pre-clinical and clinical performances of patenting and new oral insulin delivery systems formulated from polysaccharides, such as chitosan and alginate, in the form of nanoparticles. Their effectiveness at pre-clinical and clinical stages will be highlighted to provide an updated insight on the efforts devoted by researchers and industrialists. © 2012 Springer-Verlag Berlin Heidelberg. All rights are reserved.
Springer-Verlag Berlin Heidelberg

English
Book chapter
author Wong T.W.; Mandal U.; Shen L.-J.
spellingShingle Wong T.W.; Mandal U.; Shen L.-J.
Chitosan and alginate nanoparticles as oral insulin carrier
author_facet Wong T.W.; Mandal U.; Shen L.-J.
author_sort Wong T.W.; Mandal U.; Shen L.-J.
title Chitosan and alginate nanoparticles as oral insulin carrier
title_short Chitosan and alginate nanoparticles as oral insulin carrier
title_full Chitosan and alginate nanoparticles as oral insulin carrier
title_fullStr Chitosan and alginate nanoparticles as oral insulin carrier
title_full_unstemmed Chitosan and alginate nanoparticles as oral insulin carrier
title_sort Chitosan and alginate nanoparticles as oral insulin carrier
publishDate 2012
container_title Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities
container_volume 9.78364E+12
container_issue
doi_str_mv 10.1007/978-3-642-29265-1_11
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901035283&doi=10.1007%2f978-3-642-29265-1_11&partnerID=40&md5=cdea40bc1d4d8b2c3f84d719798b4ef1
description The possibility of administering insulin orally instead of through painful subcutaneous route has been investigated over years in the arena of diabetes medicine. Nanoparticles, microparticles, hydrogel, capsule, tablet and film patch are dosage forms designed to deliver insulin orally. They are largely formulated with polymeric adhesive, protease inhibitor, insulin aggregation inhibitor and functional excipients to induce transcellular, paracellular, Peyers patches or receptor mediated transport of insulin in gastrointestinal tract. This review probes into pre-clinical and clinical performances of patenting and new oral insulin delivery systems formulated from polysaccharides, such as chitosan and alginate, in the form of nanoparticles. Their effectiveness at pre-clinical and clinical stages will be highlighted to provide an updated insight on the efforts devoted by researchers and industrialists. © 2012 Springer-Verlag Berlin Heidelberg. All rights are reserved.
publisher Springer-Verlag Berlin Heidelberg
issn
language English
format Book chapter
accesstype
record_format scopus
collection Scopus
_version_ 1812871802196590592

Similar Items